Nan Fung Group Holdings Ltd purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 30,875 shares of the company's stock, valued at approximately $3,540,436,000. Kymera Therapeutics makes up approximately 2.7% of Nan Fung Group Holdings Ltd's holdings, making the stock its 11th biggest holding.
Several other institutional investors and hedge funds also recently bought and sold shares of KYMR. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after buying an additional 98 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after acquiring an additional 349 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the fourth quarter valued at $63,000. Finally, Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter.
Kymera Therapeutics Stock Up 1.0%
Shares of KYMR stock opened at $121.05 on Tuesday. The stock has a fifty day moving average of $110.13 and a 200 day moving average of $92.46. The firm has a market capitalization of $10.07 billion, a price-to-earnings ratio of -37.36 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52 week low of $39.84 and a 52 week high of $130.05.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. Kymera Therapeutics's quarterly revenue was up 465.2% compared to the same quarter last year. During the same period last year, the business posted ($0.95) earnings per share. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the sale, the director directly owned 240,123 shares of the company's stock, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Noah Goodman sold 3,389 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider owned 47,179 shares in the company, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 3,591,908 shares of company stock valued at $386,532,863. Insiders own 15.98% of the company's stock.
Analyst Ratings Changes
Several analysts have issued reports on KYMR shares. Mizuho increased their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an "outperform" rating in a research note on Thursday, July 16th. Barclays upped their price target on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Oppenheimer restated an "outperform" rating and issued a $125.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. B. Riley Financial raised their price objective on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Finally, Brookline Capital Markets reaffirmed a "buy" rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $125.65.
Read Our Latest Report on Kymera Therapeutics
About Kymera Therapeutics
(
Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Articles
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
